[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fO-mTt_o69vFKFhyXDZZxkVEvx4zi7GA5VeK-ExfSXbY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":52,"rows":59},"Medstar Health Research Institute",[4],157,false,34,6,29397,5,109,[14,17,19,21,23,26,28,30],{"name":15,"count":16},"Cancer",7,{"name":18,"count":9},"Coronary Artery Disease",{"name":20,"count":9},"Neurogenic Bladder",{"name":22,"count":11},"Pelvic Organ Prolapse",{"name":24,"count":25},"Heart Failure",4,{"name":27,"count":25},"Breast Cancer",{"name":29,"count":25},"Burn Scar",{"name":31,"count":25},"Diabetes Mellitus",[33,38,43,47],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT05230511","Intravesical LGG VS Saline Bladder Wash RCT","2026-07-31","Lactobacillus RhamnosusGG",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04323735","Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters","2026-09","Culturelle 10 Billion CFU",{"nctId":44,"briefTitle":45,"date":41,"intervention":46},"NCT07301008","Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US","Rimegepant 75 MG",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07308808","Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation","2027-03-30","Lactobacillus Crispatus",[53,54,55,56,57,58],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[60,86,117,139,157,178,213,239,263,289,307,335,353,381,407,425,449,473,496,520,544,568,591,609,635,674,711,733,767,791,809,834,868,886,911,936,954,972,999,1017,1039,1057,1075,1093,1111,1129,1147,1165,1191,1209,1234,1264,1296,1329,1359,1377,1402,1428,1446,1472,1498,1516,1534,1560,1587],{"intervention":46,"totalTrials":61,"cells":62},1,{"EARLY_PHASE1":63,"PHASE1":66,"PHASE2":68,"PHASE3":70,"PHASE4":72,"NA":84},{"trials":64,"activeCount":65},[],0,{"trials":67,"activeCount":65},[],{"trials":69,"activeCount":65},[],{"trials":71,"activeCount":65},[],{"trials":73,"activeCount":61,"soonestReadout":41},[74],{"nctId":44,"briefTitle":45,"status":75,"phases":76,"primaryCompletion":41,"completion":77,"start":78,"enrollment":79,"conditions":80,"interventions":83},"RECRUITING",[57],"2027-01","2025-09-09",60,[81,82],"Migraine","Trigger Induced Migraine",[46],{"trials":85,"activeCount":65},[],{"intervention":42,"totalTrials":87,"cells":88},2,{"EARLY_PHASE1":89,"PHASE1":91,"PHASE2":93,"PHASE3":111,"PHASE4":113,"NA":115},{"trials":90,"activeCount":65},[],{"trials":92,"activeCount":65},[],{"trials":94,"activeCount":61,"soonestReadout":41},[95,101],{"nctId":39,"briefTitle":40,"status":75,"phases":96,"primaryCompletion":41,"completion":41,"start":97,"enrollment":98,"conditions":99,"interventions":100},[55],"2020-01-10",182,[20],[42],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":98,"conditions":108,"interventions":110},"NCT04373512","Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury","COMPLETED",[55],"2025-02-14","2020-05-20",[109,20],"Spinal Cord Injuries",[42,42],{"trials":112,"activeCount":65},[],{"trials":114,"activeCount":65},[],{"trials":116,"activeCount":65},[],{"intervention":37,"totalTrials":61,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":133,"PHASE4":135,"NA":137},{"trials":120,"activeCount":65},[],{"trials":122,"activeCount":65},[],{"trials":124,"activeCount":61,"soonestReadout":36},[125],{"nctId":34,"briefTitle":35,"status":75,"phases":126,"primaryCompletion":36,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},[55],"2026-12-31","2022-06-13",120,[109,20],[37,132],"Saline bladder wash",{"trials":134,"activeCount":65},[],{"trials":136,"activeCount":65},[],{"trials":138,"activeCount":65},[],{"intervention":132,"totalTrials":61,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":151,"PHASE4":153,"NA":155},{"trials":142,"activeCount":65},[],{"trials":144,"activeCount":65},[],{"trials":146,"activeCount":61,"soonestReadout":36},[147],{"nctId":34,"briefTitle":35,"status":75,"phases":148,"primaryCompletion":36,"completion":127,"start":128,"enrollment":129,"conditions":149,"interventions":150},[55],[109,20],[37,132],{"trials":152,"activeCount":65},[],{"trials":154,"activeCount":65},[],{"trials":156,"activeCount":65},[],{"intervention":51,"totalTrials":61,"cells":158},{"EARLY_PHASE1":159,"PHASE1":168,"PHASE2":170,"PHASE3":172,"PHASE4":174,"NA":176},{"trials":160,"activeCount":61,"soonestReadout":50},[161],{"nctId":48,"briefTitle":49,"status":75,"phases":162,"primaryCompletion":50,"completion":50,"start":78,"enrollment":163,"conditions":164,"interventions":167},[53],40,[165,20,166],"Spinal Cord Injuries (SCI)","Urinary Tract Infection (Diagnosis)",[51],{"trials":169,"activeCount":65},[],{"trials":171,"activeCount":65},[],{"trials":173,"activeCount":65},[],{"trials":175,"activeCount":65},[],{"trials":177,"activeCount":65},[],{"intervention":179,"totalTrials":87,"cells":180},"Clobetasol Propionate 0.05% ointment",{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":187,"PHASE4":199,"NA":211},{"trials":182,"activeCount":65},[],{"trials":184,"activeCount":65},[],{"trials":186,"activeCount":65},[],{"trials":188,"activeCount":65},[189],{"nctId":190,"briefTitle":191,"status":104,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":198},"NCT02573883","Clobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus",[56],"2019-09","2015-10",52,[197],"Vulvar Lichen Sclerosus",[179],{"trials":200,"activeCount":65},[201],{"nctId":202,"briefTitle":203,"status":104,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":209},"NCT04951206","Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus",[57],"2025-04-25","2022-03-01",212,[197],[210],"Clobetasol Propionate 0.05% Ointment",{"trials":212,"activeCount":65},[],{"intervention":214,"totalTrials":61,"cells":215},"Premarin vaginal estrogen cream",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":237},{"trials":217,"activeCount":65},[],{"trials":219,"activeCount":65},[],{"trials":221,"activeCount":65},[],{"trials":223,"activeCount":65},[],{"trials":225,"activeCount":65},[226],{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":236},"NCT02213757","Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)","TERMINATED",[57],"2015-12","2014-08",29,[235],"Microscopic Hematuria",[214],{"trials":238,"activeCount":65},[],{"intervention":240,"totalTrials":61,"cells":241},"99mTc sestamibi",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":261},{"trials":243,"activeCount":65},[],{"trials":245,"activeCount":65},[],{"trials":247,"activeCount":65},[],{"trials":249,"activeCount":65},[],{"trials":251,"activeCount":65},[252],{"nctId":253,"briefTitle":254,"status":229,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":25,"conditions":258,"interventions":260},"NCT03065218","99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients",[57],"2021-02-15","2016-10",[259],"Thyroid Cancer",[240],{"trials":262,"activeCount":65},[],{"intervention":264,"totalTrials":61,"cells":265},"Mifepristone",{"EARLY_PHASE1":266,"PHASE1":268,"PHASE2":270,"PHASE3":272,"PHASE4":274,"NA":287},{"trials":267,"activeCount":65},[],{"trials":269,"activeCount":65},[],{"trials":271,"activeCount":65},[],{"trials":273,"activeCount":65},[],{"trials":275,"activeCount":65},[276],{"nctId":277,"briefTitle":278,"status":104,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":283,"interventions":285},"NCT02412618","Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation",[57],"2014-01","2012-09",100,[284],"Induced Abortion",[264,286],"Misoprostol",{"trials":288,"activeCount":65},[],{"intervention":286,"totalTrials":61,"cells":290},{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":297,"PHASE4":299,"NA":305},{"trials":292,"activeCount":65},[],{"trials":294,"activeCount":65},[],{"trials":296,"activeCount":65},[],{"trials":298,"activeCount":65},[],{"trials":300,"activeCount":65},[301],{"nctId":277,"briefTitle":278,"status":104,"phases":302,"primaryCompletion":280,"completion":280,"start":281,"enrollment":282,"conditions":303,"interventions":304},[57],[284],[264,286],{"trials":306,"activeCount":65},[],{"intervention":308,"totalTrials":61,"cells":309},"Cefazolin",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":333},{"trials":311,"activeCount":65},[],{"trials":313,"activeCount":65},[],{"trials":315,"activeCount":65},[],{"trials":317,"activeCount":65},[],{"trials":319,"activeCount":65},[320],{"nctId":321,"briefTitle":322,"status":104,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":331},"NCT04516148","A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting",[57],"2020-10-30","2018-05-29",32,[328,329,330],"Burn","Surgery","Infection Wound",[308,332],"Clindamycin",{"trials":334,"activeCount":65},[],{"intervention":332,"totalTrials":61,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":351},{"trials":338,"activeCount":65},[],{"trials":340,"activeCount":65},[],{"trials":342,"activeCount":65},[],{"trials":344,"activeCount":65},[],{"trials":346,"activeCount":65},[347],{"nctId":321,"briefTitle":322,"status":104,"phases":348,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":349,"interventions":350},[57],[328,329,330],[308,332],{"trials":352,"activeCount":65},[],{"intervention":354,"totalTrials":61,"cells":355},"Quadrivalent HPV for types 6, 11, 16 and 18",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":364,"NA":379},{"trials":357,"activeCount":65},[],{"trials":359,"activeCount":65},[],{"trials":361,"activeCount":65},[],{"trials":363,"activeCount":65},[],{"trials":365,"activeCount":65},[366],{"nctId":367,"briefTitle":368,"status":104,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":378},"NCT01101750","Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?",[57],"2012-01-20","2012-12-14","2010-05",25,[375,376,377],"Cervical Cancer","Hpv","Warts",[354],{"trials":380,"activeCount":65},[],{"intervention":382,"totalTrials":61,"cells":383},"Midodrine",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":405},{"trials":385,"activeCount":65},[],{"trials":387,"activeCount":65},[],{"trials":389,"activeCount":65},[],{"trials":391,"activeCount":65},[],{"trials":393,"activeCount":65},[394],{"nctId":395,"briefTitle":396,"status":229,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT04668859","Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome",[57],"2018-08-08","2016-07-29",10,[402],"Use of Midodrine in Post-cardiopulmonary Bypass Vasoplegic Syndrome",[382,404],"Methylcellulose",{"trials":406,"activeCount":65},[],{"intervention":404,"totalTrials":61,"cells":408},{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":423},{"trials":410,"activeCount":65},[],{"trials":412,"activeCount":65},[],{"trials":414,"activeCount":65},[],{"trials":416,"activeCount":65},[],{"trials":418,"activeCount":65},[419],{"nctId":395,"briefTitle":396,"status":229,"phases":420,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":421,"interventions":422},[57],[402],[382,404],{"trials":424,"activeCount":65},[],{"intervention":426,"totalTrials":61,"cells":427},"Rifabutin, Clarithromycin, and Clofazimine",{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":447},{"trials":429,"activeCount":65},[],{"trials":431,"activeCount":65},[],{"trials":433,"activeCount":65},[],{"trials":435,"activeCount":65},[],{"trials":437,"activeCount":65},[438],{"nctId":439,"briefTitle":440,"status":441,"phases":442,"primaryCompletion":443,"completion":443,"start":443,"enrollment":65,"conditions":444,"interventions":446},"NCT00513552","Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis","WITHDRAWN",[57],"2007-07",[445],"Crohn's Disease",[426],{"trials":448,"activeCount":65},[],{"intervention":450,"totalTrials":61,"cells":451},"ABLC",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":471},{"trials":453,"activeCount":65},[],{"trials":455,"activeCount":65},[],{"trials":457,"activeCount":65},[],{"trials":459,"activeCount":65},[],{"trials":461,"activeCount":65},[462],{"nctId":463,"briefTitle":464,"status":441,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":65,"conditions":468,"interventions":470},"NCT01656382","Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex",[57],"2010-01","2007-01",[469],"Invasive Cryptococcosis",[450],{"trials":472,"activeCount":65},[],{"intervention":474,"totalTrials":61,"cells":475},"Esomeprazole Magnesium",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":494},{"trials":477,"activeCount":65},[],{"trials":479,"activeCount":65},[],{"trials":481,"activeCount":65},[],{"trials":483,"activeCount":65},[],{"trials":485,"activeCount":65},[486],{"nctId":487,"briefTitle":488,"status":441,"phases":489,"primaryCompletion":490,"completion":490,"start":490,"enrollment":65,"conditions":491,"interventions":493},"NCT00443963","Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs",[57],"2006-12",[492],"Dyspepsia",[474],{"trials":495,"activeCount":65},[],{"intervention":497,"totalTrials":61,"cells":498},"Prasugrel",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":518},{"trials":500,"activeCount":65},[],{"trials":502,"activeCount":65},[],{"trials":504,"activeCount":65},[],{"trials":506,"activeCount":65},[],{"trials":508,"activeCount":65},[509],{"nctId":510,"briefTitle":511,"status":104,"phases":512,"primaryCompletion":280,"completion":280,"start":513,"enrollment":514,"conditions":515,"interventions":517},"NCT01365221","The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel",[57],"2010-10",77,[516],"Acute Coronary Syndrome",[497,497],{"trials":519,"activeCount":65},[],{"intervention":521,"totalTrials":61,"cells":522},"rosiglitazone",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":529,"PHASE4":540,"NA":542},{"trials":524,"activeCount":65},[],{"trials":526,"activeCount":65},[],{"trials":528,"activeCount":65},[],{"trials":530,"activeCount":65},[531],{"nctId":532,"briefTitle":533,"status":229,"phases":534,"primaryCompletion":443,"completion":443,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT00465296","Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS",[56],"2006-01",200,[538],"Metabolic Syndrome",[521],{"trials":541,"activeCount":65},[],{"trials":543,"activeCount":65},[],{"intervention":545,"totalTrials":61,"cells":546},"Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin",{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":564,"NA":566},{"trials":548,"activeCount":65},[],{"trials":550,"activeCount":65},[],{"trials":552,"activeCount":65},[],{"trials":554,"activeCount":65},[555],{"nctId":556,"briefTitle":557,"status":104,"phases":558,"primaryCompletion":559,"completion":559,"start":560,"enrollment":282,"conditions":561,"interventions":563},"NCT00464087","Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI",[56],"2010-11","2007-06",[562],"Acute Coronary Syndromes",[545],{"trials":565,"activeCount":65},[],{"trials":567,"activeCount":65},[],{"intervention":569,"totalTrials":61,"cells":570},"capecitabine",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":587,"NA":589},{"trials":572,"activeCount":65},[],{"trials":574,"activeCount":65},[],{"trials":576,"activeCount":65},[],{"trials":578,"activeCount":65},[579],{"nctId":580,"briefTitle":581,"status":441,"phases":582,"start":583,"enrollment":65,"conditions":584,"interventions":585},"NCT00397761","Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer",[55,56],"2006-07",[27],[569,586],"paclitaxel albumin-stabilized nanoparticle formulation",{"trials":588,"activeCount":65},[],{"trials":590,"activeCount":65},[],{"intervention":586,"totalTrials":61,"cells":592},{"EARLY_PHASE1":593,"PHASE1":595,"PHASE2":597,"PHASE3":599,"PHASE4":605,"NA":607},{"trials":594,"activeCount":65},[],{"trials":596,"activeCount":65},[],{"trials":598,"activeCount":65},[],{"trials":600,"activeCount":65},[601],{"nctId":580,"briefTitle":581,"status":441,"phases":602,"start":583,"enrollment":65,"conditions":603,"interventions":604},[55,56],[27],[569,586],{"trials":606,"activeCount":65},[],{"trials":608,"activeCount":65},[],{"intervention":610,"totalTrials":61,"cells":611},"eptifibitide",{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":631,"NA":633},{"trials":613,"activeCount":65},[],{"trials":615,"activeCount":65},[],{"trials":617,"activeCount":65},[],{"trials":619,"activeCount":65},[620],{"nctId":621,"briefTitle":622,"status":229,"phases":623,"primaryCompletion":624,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT00812435","Eptifibatide and ST Segment Resolution Following Primary PCI",[56],"2010-07","2011-03","2007-08",22,[629],"Myocardial Infarction",[610],{"trials":632,"activeCount":65},[],{"trials":634,"activeCount":65},[],{"intervention":636,"totalTrials":87,"cells":637},"Trastuzumab",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":639,"activeCount":65},[],{"trials":641,"activeCount":65},[],{"trials":643,"activeCount":65},[644,658],{"nctId":645,"briefTitle":646,"status":104,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":655},"NCT01904903","Cardiac Safety Study in Patients With HER2 + Breast Cancer",[55],"2019-06","2020-06","2013-10",31,[653,654],"HER2 Positive Breast Cancer","Left Ventricular Function Systolic Dysfunction",[636,656,657],"Pertuzumab","Ado Trastuzumab Emtansine",{"nctId":659,"briefTitle":660,"status":229,"phases":661,"primaryCompletion":372,"completion":662,"start":663,"enrollment":87,"conditions":664,"interventions":666},"NCT00810017","Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer",[55],"2010-06","2009-02",[665],"HER-2 Positive Metastatic Breast Cancer",[667,636],"Etoposide",{"trials":669,"activeCount":65},[],{"trials":671,"activeCount":65},[],{"trials":673,"activeCount":65},[],{"intervention":675,"totalTrials":87,"cells":676},"carboplatin",{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":678,"activeCount":65},[],{"trials":680,"activeCount":65},[],{"trials":682,"activeCount":65},[683,695],{"nctId":684,"briefTitle":685,"status":229,"phases":686,"primaryCompletion":687,"completion":688,"start":689,"enrollment":25,"conditions":690,"interventions":692},"NCT00006472","Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer",[55],"2001-11-15","2002-09-10","2000-01",[691],"Esophageal Cancer",[675,693,694],"fluorouracil","paclitaxel",{"nctId":696,"briefTitle":697,"status":104,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT00006469","Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer",[55],"2006-01-30","1999-08",30,[703],"Lung Cancer",[675,694],{"trials":706,"activeCount":65},[],{"trials":708,"activeCount":65},[],{"trials":710,"activeCount":65},[],{"intervention":694,"totalTrials":87,"cells":712},{"EARLY_PHASE1":713,"PHASE1":715,"PHASE2":717,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":714,"activeCount":65},[],{"trials":716,"activeCount":65},[],{"trials":718,"activeCount":65},[719,723],{"nctId":684,"briefTitle":685,"status":229,"phases":720,"primaryCompletion":687,"completion":688,"start":689,"enrollment":25,"conditions":721,"interventions":722},[55],[691],[675,693,694],{"nctId":696,"briefTitle":697,"status":104,"phases":724,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":725,"interventions":726},[55],[703],[675,694],{"trials":728,"activeCount":65},[],{"trials":730,"activeCount":65},[],{"trials":732,"activeCount":65},[],{"intervention":734,"totalTrials":87,"cells":735},"etoposide",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":761,"PHASE4":763,"NA":765},{"trials":737,"activeCount":65},[],{"trials":739,"activeCount":65},[],{"trials":741,"activeCount":65},[742,757],{"nctId":743,"briefTitle":744,"status":441,"phases":745,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":747,"interventions":749},"NCT00006669","Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma",[55],"1999-09",[748],"Lymphoma",[750,751,752,753,754,734,755,756],"rituximab","sargramostim","EPOCH regimen","cyclophosphamide","doxorubicin hydrochloride","prednisone","vincristine sulfate",{"nctId":659,"briefTitle":660,"status":229,"phases":758,"primaryCompletion":372,"completion":662,"start":663,"enrollment":87,"conditions":759,"interventions":760},[55],[665],[667,636],{"trials":762,"activeCount":65},[],{"trials":764,"activeCount":65},[],{"trials":766,"activeCount":65},[],{"intervention":768,"totalTrials":61,"cells":769},"docetaxel",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":771,"activeCount":65},[],{"trials":773,"activeCount":65},[],{"trials":775,"activeCount":65},[776],{"nctId":777,"briefTitle":778,"status":104,"phases":779,"primaryCompletion":780,"completion":780,"start":781,"conditions":782,"interventions":783},"NCT00006682","Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer",[55],"2002-01-22","2000-02",[27],[768,784],"vinorelbine ditartrate",{"trials":786,"activeCount":65},[],{"trials":788,"activeCount":65},[],{"trials":790,"activeCount":65},[],{"intervention":784,"totalTrials":61,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":794,"activeCount":65},[],{"trials":796,"activeCount":65},[],{"trials":798,"activeCount":65},[799],{"nctId":777,"briefTitle":778,"status":104,"phases":800,"primaryCompletion":780,"completion":780,"start":781,"conditions":801,"interventions":802},[55],[27],[768,784],{"trials":804,"activeCount":65},[],{"trials":806,"activeCount":65},[],{"trials":808,"activeCount":65},[],{"intervention":810,"totalTrials":61,"cells":811},"Intraperitoneal Gemcitabine",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":828,"PHASE4":830,"NA":832},{"trials":813,"activeCount":65},[],{"trials":815,"activeCount":65},[],{"trials":817,"activeCount":65},[818],{"nctId":819,"briefTitle":820,"status":229,"phases":821,"primaryCompletion":822,"completion":822,"start":823,"enrollment":824,"conditions":825,"interventions":827},"NCT01206296","Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma",[55],"2014-02","2010-08",9,[826],"Pancreatic Adenocarcinoma",[810],{"trials":829,"activeCount":65},[],{"trials":831,"activeCount":65},[],{"trials":833,"activeCount":65},[],{"intervention":835,"totalTrials":61,"cells":836},"Bimatoprost",{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":862,"PHASE4":864,"NA":866},{"trials":838,"activeCount":65},[],{"trials":840,"activeCount":65},[],{"trials":842,"activeCount":65},[843],{"nctId":844,"briefTitle":845,"status":846,"phases":847,"primaryCompletion":848,"completion":849,"start":850,"enrollment":373,"conditions":851,"interventions":860},"NCT06122090","Treatment of Hypopigmented Scars With Bimatoprost","UNKNOWN",[55],"2024-12-30","2025-07-31","2023-07-18",[852,853,854,29,855,856,857,858,859],"Scars","Hypopigmented Scar","Hypopigmented Skin","Scarring","Cicatrix, Hypertrophic","Cicatrix","Pigmentation Disorder","Burns Laser",[835,861],"Saline",{"trials":863,"activeCount":65},[],{"trials":865,"activeCount":65},[],{"trials":867,"activeCount":65},[],{"intervention":861,"totalTrials":61,"cells":869},{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":880,"PHASE4":882,"NA":884},{"trials":871,"activeCount":65},[],{"trials":873,"activeCount":65},[],{"trials":875,"activeCount":65},[876],{"nctId":844,"briefTitle":845,"status":846,"phases":877,"primaryCompletion":848,"completion":849,"start":850,"enrollment":373,"conditions":878,"interventions":879},[55],[852,853,854,29,855,856,857,858,859],[835,861],{"trials":881,"activeCount":65},[],{"trials":883,"activeCount":65},[],{"trials":885,"activeCount":65},[],{"intervention":887,"totalTrials":61,"cells":888},"Human Allogeneic Mesenchymal Bone Marrow Cells",{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":905,"PHASE4":907,"NA":909},{"trials":890,"activeCount":65},[],{"trials":892,"activeCount":65},[],{"trials":894,"activeCount":65},[895],{"nctId":896,"briefTitle":897,"status":229,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":25,"conditions":901,"interventions":904},"NCT03925324","Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device",[55],"2021-08-16","2019-05-03",[902,903],"Ischemic Heart Disease","Non-ischemic Cardiomyopathy",[887],{"trials":906,"activeCount":65},[],{"trials":908,"activeCount":65},[],{"trials":910,"activeCount":65},[],{"intervention":912,"totalTrials":61,"cells":913},"Lactobacillus rhamnosus GG",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":930,"PHASE4":932,"NA":934},{"trials":915,"activeCount":65},[],{"trials":917,"activeCount":65},[],{"trials":919,"activeCount":65},[920],{"nctId":921,"briefTitle":922,"status":104,"phases":923,"primaryCompletion":924,"completion":924,"start":925,"enrollment":926,"conditions":927,"interventions":929},"NCT02748317","Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB",[55],"2018-10-31","2016-01",96,[928],"Lower Urinary Tract Symptoms",[912],{"trials":931,"activeCount":65},[],{"trials":933,"activeCount":65},[],{"trials":935,"activeCount":65},[],{"intervention":656,"totalTrials":61,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":939,"activeCount":65},[],{"trials":941,"activeCount":65},[],{"trials":943,"activeCount":65},[944],{"nctId":645,"briefTitle":646,"status":104,"phases":945,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":946,"interventions":947},[55],[653,654],[636,656,657],{"trials":949,"activeCount":65},[],{"trials":951,"activeCount":65},[],{"trials":953,"activeCount":65},[],{"intervention":657,"totalTrials":61,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":966,"PHASE4":968,"NA":970},{"trials":957,"activeCount":65},[],{"trials":959,"activeCount":65},[],{"trials":961,"activeCount":65},[962],{"nctId":645,"briefTitle":646,"status":104,"phases":963,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":964,"interventions":965},[55],[653,654],[636,656,657],{"trials":967,"activeCount":65},[],{"trials":969,"activeCount":65},[],{"trials":971,"activeCount":65},[],{"intervention":973,"totalTrials":61,"cells":974},"SU011248, Sutent",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":976,"activeCount":65},[],{"trials":978,"activeCount":65},[],{"trials":980,"activeCount":65},[981],{"nctId":982,"briefTitle":983,"status":104,"phases":984,"primaryCompletion":985,"completion":231,"start":986,"enrollment":987,"conditions":988,"interventions":992},"NCT00668811","Sutent Adjunctive Treatment of Differentiated Thyroid Cancer",[55],"2015-09","2008-04",23,[989,990,991],"Papillary Thyroid Cancer","Follicular Thyroid Cancer","Differentiated Thyroid Cancer",[973],{"trials":994,"activeCount":65},[],{"trials":996,"activeCount":65},[],{"trials":998,"activeCount":65},[],{"intervention":693,"totalTrials":61,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1005,"PHASE3":1011,"PHASE4":1013,"NA":1015},{"trials":1002,"activeCount":65},[],{"trials":1004,"activeCount":65},[],{"trials":1006,"activeCount":65},[1007],{"nctId":684,"briefTitle":685,"status":229,"phases":1008,"primaryCompletion":687,"completion":688,"start":689,"enrollment":25,"conditions":1009,"interventions":1010},[55],[691],[675,693,694],{"trials":1012,"activeCount":65},[],{"trials":1014,"activeCount":65},[],{"trials":1016,"activeCount":65},[],{"intervention":1018,"totalTrials":61,"cells":1019},"Lactobacillus",{"EARLY_PHASE1":1020,"PHASE1":1022,"PHASE2":1024,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1021,"activeCount":65},[],{"trials":1023,"activeCount":65},[],{"trials":1025,"activeCount":65},[1026],{"nctId":1027,"briefTitle":922,"status":104,"phases":1028,"primaryCompletion":1029,"completion":1030,"start":925,"enrollment":16,"conditions":1031,"interventions":1032},"NCT02748356",[55],"2018-10-21","2018-12-31",[928],[1018],{"trials":1034,"activeCount":65},[],{"trials":1036,"activeCount":65},[],{"trials":1038,"activeCount":65},[],{"intervention":750,"totalTrials":61,"cells":1040},{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1051,"PHASE4":1053,"NA":1055},{"trials":1042,"activeCount":65},[],{"trials":1044,"activeCount":65},[],{"trials":1046,"activeCount":65},[1047],{"nctId":743,"briefTitle":744,"status":441,"phases":1048,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1049,"interventions":1050},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1052,"activeCount":65},[],{"trials":1054,"activeCount":65},[],{"trials":1056,"activeCount":65},[],{"intervention":751,"totalTrials":61,"cells":1058},{"EARLY_PHASE1":1059,"PHASE1":1061,"PHASE2":1063,"PHASE3":1069,"PHASE4":1071,"NA":1073},{"trials":1060,"activeCount":65},[],{"trials":1062,"activeCount":65},[],{"trials":1064,"activeCount":65},[1065],{"nctId":743,"briefTitle":744,"status":441,"phases":1066,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1067,"interventions":1068},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1070,"activeCount":65},[],{"trials":1072,"activeCount":65},[],{"trials":1074,"activeCount":65},[],{"intervention":752,"totalTrials":61,"cells":1076},{"EARLY_PHASE1":1077,"PHASE1":1079,"PHASE2":1081,"PHASE3":1087,"PHASE4":1089,"NA":1091},{"trials":1078,"activeCount":65},[],{"trials":1080,"activeCount":65},[],{"trials":1082,"activeCount":65},[1083],{"nctId":743,"briefTitle":744,"status":441,"phases":1084,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1085,"interventions":1086},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1088,"activeCount":65},[],{"trials":1090,"activeCount":65},[],{"trials":1092,"activeCount":65},[],{"intervention":753,"totalTrials":61,"cells":1094},{"EARLY_PHASE1":1095,"PHASE1":1097,"PHASE2":1099,"PHASE3":1105,"PHASE4":1107,"NA":1109},{"trials":1096,"activeCount":65},[],{"trials":1098,"activeCount":65},[],{"trials":1100,"activeCount":65},[1101],{"nctId":743,"briefTitle":744,"status":441,"phases":1102,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1103,"interventions":1104},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1106,"activeCount":65},[],{"trials":1108,"activeCount":65},[],{"trials":1110,"activeCount":65},[],{"intervention":754,"totalTrials":61,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1114,"activeCount":65},[],{"trials":1116,"activeCount":65},[],{"trials":1118,"activeCount":65},[1119],{"nctId":743,"briefTitle":744,"status":441,"phases":1120,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1121,"interventions":1122},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1124,"activeCount":65},[],{"trials":1126,"activeCount":65},[],{"trials":1128,"activeCount":65},[],{"intervention":755,"totalTrials":61,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1132,"activeCount":65},[],{"trials":1134,"activeCount":65},[],{"trials":1136,"activeCount":65},[1137],{"nctId":743,"briefTitle":744,"status":441,"phases":1138,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1139,"interventions":1140},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1142,"activeCount":65},[],{"trials":1144,"activeCount":65},[],{"trials":1146,"activeCount":65},[],{"intervention":756,"totalTrials":61,"cells":1148},{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1150,"activeCount":65},[],{"trials":1152,"activeCount":65},[],{"trials":1154,"activeCount":65},[1155],{"nctId":743,"briefTitle":744,"status":441,"phases":1156,"primaryCompletion":689,"completion":689,"start":746,"enrollment":65,"conditions":1157,"interventions":1158},[55],[748],[750,751,752,753,754,734,755,756],{"trials":1160,"activeCount":65},[],{"trials":1162,"activeCount":65},[],{"trials":1164,"activeCount":65},[],{"intervention":1166,"totalTrials":61,"cells":1167},"ixabepilone",{"EARLY_PHASE1":1168,"PHASE1":1170,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1169,"activeCount":65},[],{"trials":1171,"activeCount":65},[1172],{"nctId":1173,"briefTitle":1174,"status":104,"phases":1175,"primaryCompletion":1176,"completion":1176,"start":1177,"enrollment":1178,"conditions":1179,"interventions":1181},"NCT00717704","Solid Tumors Using Ixabepilone and Dasatinib",[54],"2011-05","2008-07",19,[1180],"Solid Tumor",[1166,1182],"Dasatinib",{"trials":1184,"activeCount":65},[],{"trials":1186,"activeCount":65},[],{"trials":1188,"activeCount":65},[],{"trials":1190,"activeCount":65},[],{"intervention":1182,"totalTrials":61,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":65},[],{"trials":1196,"activeCount":65},[1197],{"nctId":1173,"briefTitle":1174,"status":104,"phases":1198,"primaryCompletion":1176,"completion":1176,"start":1177,"enrollment":1178,"conditions":1199,"interventions":1200},[54],[1180],[1166,1182],{"trials":1202,"activeCount":65},[],{"trials":1204,"activeCount":65},[],{"trials":1206,"activeCount":65},[],{"trials":1208,"activeCount":65},[],{"intervention":1210,"totalTrials":61,"cells":1211},"Ketorolac",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1232},{"trials":1213,"activeCount":65},[],{"trials":1215,"activeCount":65},[1216],{"nctId":1217,"briefTitle":1218,"status":846,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":163,"conditions":1222,"interventions":1224},"NCT05054868","Ketorolac vs Oxycodone for Great Toe Arthrodesis",[54],"2024-07-31","2020-04-14",[1223],"Arthrodesis",[1225,1210],"Oxycodone",{"trials":1227,"activeCount":65},[],{"trials":1229,"activeCount":65},[],{"trials":1231,"activeCount":65},[],{"trials":1233,"activeCount":65},[],{"intervention":1225,"totalTrials":87,"cells":1235},{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1237,"activeCount":65},[],{"trials":1239,"activeCount":65},[1240],{"nctId":1217,"briefTitle":1218,"status":846,"phases":1241,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":163,"conditions":1242,"interventions":1243},[54],[1223],[1225,1210],{"trials":1245,"activeCount":65},[],{"trials":1247,"activeCount":65},[],{"trials":1249,"activeCount":65},[],{"trials":1251,"activeCount":65},[1252],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1262},"NCT03959969","Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery",[58],"2019-12-28","2020-01-11","2019-07-17",48,[1261],"Opioid Use, Unspecified",[1263,1225],"Ibuprofen",{"intervention":1265,"totalTrials":87,"cells":1266},"Ticagrelor",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1285},{"trials":1268,"activeCount":65},[],{"trials":1270,"activeCount":65},[],{"trials":1272,"activeCount":65},[],{"trials":1274,"activeCount":65},[],{"trials":1276,"activeCount":65},[1277],{"nctId":1278,"briefTitle":1279,"status":104,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":701,"conditions":1283,"interventions":1284},"NCT02282332","NIRS Ticagrelor Evaluation",[57],"2016-04","2014-06",[18],[1265],{"trials":1286,"activeCount":65},[1287],{"nctId":1288,"briefTitle":1289,"status":104,"phases":1290,"primaryCompletion":1291,"completion":1292,"start":1293,"enrollment":25,"conditions":1294,"interventions":1295},"NCT01829659","The ACS Ethnicity Platelet Function Study",[],"2016-03","2016-05","2013-05",[516],[1265],{"intervention":1297,"totalTrials":87,"cells":1298},"Gabapentin",{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1305,"PHASE4":1307,"NA":1319},{"trials":1300,"activeCount":65},[],{"trials":1302,"activeCount":65},[],{"trials":1304,"activeCount":65},[],{"trials":1306,"activeCount":65},[],{"trials":1308,"activeCount":65},[1309],{"nctId":1310,"briefTitle":1311,"status":104,"phases":1312,"primaryCompletion":1313,"completion":107,"start":1314,"enrollment":1315,"conditions":1316,"interventions":1318},"NCT03635905","Gabapentin for Pain Management During Dilation and Evacuation",[57],"2019-05-09","2017-05-26",130,[1317],"Pain",[1297],{"trials":1320,"activeCount":65},[1321],{"nctId":1322,"briefTitle":1323,"status":104,"phases":1324,"primaryCompletion":1325,"completion":1325,"start":280,"enrollment":400,"conditions":1326,"interventions":1328},"NCT04345432","Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS)",[58],"2017-09",[1327],"Postural Orthostatic Tachycardia Syndrome",[1297],{"intervention":1330,"totalTrials":61,"cells":1331},"Modern medical management",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1342},{"trials":1333,"activeCount":65},[],{"trials":1335,"activeCount":65},[],{"trials":1337,"activeCount":65},[],{"trials":1339,"activeCount":65},[],{"trials":1341,"activeCount":65},[],{"trials":1343,"activeCount":65},[1344],{"nctId":1345,"briefTitle":1346,"status":104,"phases":1347,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1357},"NCT00074724","Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization",[58],"2008-12","2017-04","2003-05",319,[1353,1354,24,1355,1356],"Cardiovascular Diseases","Coronary Disease","Heart Failure, Congestive","Heart Diseases",[1330,1358],"Optimal medical therapy",{"intervention":1358,"totalTrials":61,"cells":1360},{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1367,"PHASE4":1369,"NA":1371},{"trials":1362,"activeCount":65},[],{"trials":1364,"activeCount":65},[],{"trials":1366,"activeCount":65},[],{"trials":1368,"activeCount":65},[],{"trials":1370,"activeCount":65},[],{"trials":1372,"activeCount":65},[1373],{"nctId":1345,"briefTitle":1346,"status":104,"phases":1374,"primaryCompletion":1348,"completion":1349,"start":1350,"enrollment":1351,"conditions":1375,"interventions":1376},[58],[1353,1354,24,1355,1356],[1330,1358],{"intervention":1378,"totalTrials":61,"cells":1379},"OnabotulinumtoxinA",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1390},{"trials":1381,"activeCount":65},[],{"trials":1383,"activeCount":65},[],{"trials":1385,"activeCount":65},[],{"trials":1387,"activeCount":65},[],{"trials":1389,"activeCount":65},[],{"trials":1391,"activeCount":65},[1392],{"nctId":1393,"briefTitle":1394,"status":229,"phases":1395,"primaryCompletion":1396,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT04451382","PTNS vs Botox of Refractory OAB",[],"2018-12","2015-03",150,[1400],"Overactive Bladder (OAB)",[1378],{"intervention":1403,"totalTrials":61,"cells":1404},"Anticholinergic",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1406,"activeCount":65},[],{"trials":1408,"activeCount":65},[],{"trials":1410,"activeCount":65},[],{"trials":1412,"activeCount":65},[],{"trials":1414,"activeCount":65},[],{"trials":1416,"activeCount":65},[1417],{"nctId":1418,"briefTitle":1419,"status":104,"phases":1420,"primaryCompletion":1421,"completion":1421,"start":1422,"enrollment":1423,"conditions":1424,"interventions":1427},"NCT03500146","Sexual Function Trial of Overactive Bladder: Medication Versus PTNS",[],"2019-09-30","2017-01-30",175,[1425,1426],"Female Sexual Dysfunction","Overactive Bladder",[1403],{"intervention":1263,"totalTrials":61,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1436,"PHASE4":1438,"NA":1440},{"trials":1431,"activeCount":65},[],{"trials":1433,"activeCount":65},[],{"trials":1435,"activeCount":65},[],{"trials":1437,"activeCount":65},[],{"trials":1439,"activeCount":65},[],{"trials":1441,"activeCount":65},[1442],{"nctId":1253,"briefTitle":1254,"status":104,"phases":1443,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":1259,"conditions":1444,"interventions":1445},[58],[1261],[1263,1225],{"intervention":1447,"totalTrials":61,"cells":1448},"Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and\u002For insulin",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1457,"NA":1459},{"trials":1450,"activeCount":65},[],{"trials":1452,"activeCount":65},[],{"trials":1454,"activeCount":65},[],{"trials":1456,"activeCount":65},[],{"trials":1458,"activeCount":65},[],{"trials":1460,"activeCount":65},[1461],{"nctId":1462,"briefTitle":1463,"status":104,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1471},"NCT01033773","Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)",[58],"2008-11","2009-01","2007-09",86,[1470],"Type 2 Diabetes Mellitus",[1447],{"intervention":1473,"totalTrials":61,"cells":1474},"Azithromycin",{"EARLY_PHASE1":1475,"PHASE1":1477,"PHASE2":1479,"PHASE3":1481,"PHASE4":1483,"NA":1485},{"trials":1476,"activeCount":65},[],{"trials":1478,"activeCount":65},[],{"trials":1480,"activeCount":65},[],{"trials":1482,"activeCount":65},[],{"trials":1484,"activeCount":65},[],{"trials":1486,"activeCount":65},[1487],{"nctId":1488,"briefTitle":1489,"status":104,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1291,"enrollment":1492,"conditions":1493,"interventions":1495},"NCT02756403","A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions",[58],"2017-07",181,[1494],"First Trimester Abortion",[1473,1496,1497],"Doxycycline","Metronidazole",{"intervention":1496,"totalTrials":61,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1501,"activeCount":65},[],{"trials":1503,"activeCount":65},[],{"trials":1505,"activeCount":65},[],{"trials":1507,"activeCount":65},[],{"trials":1509,"activeCount":65},[],{"trials":1511,"activeCount":65},[1512],{"nctId":1488,"briefTitle":1489,"status":104,"phases":1513,"primaryCompletion":1491,"completion":1491,"start":1291,"enrollment":1492,"conditions":1514,"interventions":1515},[58],[1494],[1473,1496,1497],{"intervention":1497,"totalTrials":61,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1519,"activeCount":65},[],{"trials":1521,"activeCount":65},[],{"trials":1523,"activeCount":65},[],{"trials":1525,"activeCount":65},[],{"trials":1527,"activeCount":65},[],{"trials":1529,"activeCount":65},[1530],{"nctId":1488,"briefTitle":1489,"status":104,"phases":1531,"primaryCompletion":1491,"completion":1491,"start":1291,"enrollment":1492,"conditions":1532,"interventions":1533},[58],[1494],[1473,1496,1497],{"intervention":1535,"totalTrials":61,"cells":1536},"Pharmacogenetic Testing",{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1541,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1538,"activeCount":65},[],{"trials":1540,"activeCount":65},[],{"trials":1542,"activeCount":65},[],{"trials":1544,"activeCount":65},[],{"trials":1546,"activeCount":65},[],{"trials":1548,"activeCount":65},[1549],{"nctId":1550,"briefTitle":1551,"status":846,"phases":1552,"primaryCompletion":1553,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1559},"NCT04685304","Pharmacogenomics Applied to Chronic Pain Treatment in Primary Care",[58],"2023-07-11","2024-04-11","2020-12-02",315,[1558],"Chronic Pain",[1535],{"intervention":1561,"totalTrials":61,"cells":1562},"Elagolix Oral Product",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1571,"NA":1573},{"trials":1564,"activeCount":65},[],{"trials":1566,"activeCount":65},[],{"trials":1568,"activeCount":65},[],{"trials":1570,"activeCount":65},[],{"trials":1572,"activeCount":65},[],{"trials":1574,"activeCount":65},[1575],{"nctId":1576,"briefTitle":1577,"status":846,"phases":1578,"primaryCompletion":1579,"completion":1580,"start":1581,"enrollment":1582,"conditions":1583,"interventions":1586},"NCT04856306","Myomectomy vs Uterine Artery Embolization vs GnRh Antagonist for AUB-L",[],"2025-06-30","2025-08-30","2021-04-12",300,[1584,1585],"Heavy Menstrual Bleeding","Fibroid Uterus",[1561],{"intervention":1588,"totalTrials":61,"cells":1589},"levothyroxine",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1600},{"trials":1591,"activeCount":65},[],{"trials":1593,"activeCount":65},[],{"trials":1595,"activeCount":65},[],{"trials":1597,"activeCount":65},[],{"trials":1599,"activeCount":65},[],{"trials":1601,"activeCount":65},[1602],{"nctId":1603,"briefTitle":1604,"status":104,"phases":1605,"primaryCompletion":1606,"completion":1606,"start":1607,"enrollment":79,"conditions":1608,"interventions":1611},"NCT03115515","Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy",[58],"2018-02","2011-08",[1609,1610],"Pregnancy Related","Thyroid",[1588]]